Andrea L. Hebb, Ph.D. - Publications

2002 Carleton University, Ottawa, Canada 
Behavioral Psychology, Animal Physiology Biology, Physiological Psychology, Pharmacology

25 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2010 Hebb AL, Moore CS, Bhan V, Robertson GS. Effects of IFN-B on TRAIL and Decoy Receptor Expression in Different Immune Cell Populations from MS Patients with Distinct Disease Subtypes. Autoimmune Diseases. 2011: 485752. PMID 21253524 DOI: 10.4061/2011/485752  0.48
2010 Hebb AL, Bhan V, Wishart AD, Moore CS, Robertson GS. Human kallikrein 6 cerebrospinal levels are elevated in multiple sclerosis. Current Drug Discovery Technologies. 7: 137-40. PMID 20836755 DOI: 10.2174/157016310793180611  0.48
2009 Alirezaei M, Fox HS, Flynn CT, Moore CS, Hebb AL, Frausto RF, Bhan V, Kiosses WB, Whitton JL, Robertson GS, Crocker SJ. Elevated ATG5 expression in autoimmune demyelination and multiple sclerosis. Autophagy. 5: 152-8. PMID 19066443 DOI: 10.4161/Auto.5.2.7348  0.48
2008 Moore CS, Hebb AL, Blanchard MM, Crocker CE, Liston P, Korneluk RG, Robertson GS. Increased X-linked inhibitor of apoptosis protein (XIAP) expression exacerbates experimental autoimmune encephalomyelitis (EAE). Journal of Neuroimmunology. 203: 79-93. PMID 18687476 DOI: 10.1016/J.Jneuroim.2008.06.030  0.48
2008 Hebb AL, Robertson HA. PDEs as drug targets for CNS immune disorders. Current Opinion in Investigational Drugs (London, England : 2000). 9: 744-53. PMID 18600580  0.48
2008 Hebb AL, Moore CS, Bhan V, Campbell T, Fisk JD, Robertson HA, Thorne M, Lacasse E, Holcik M, Gillard J, Crocker SJ, Robertson GS. Expression of the inhibitor of apoptosis protein family in multiple sclerosis reveals a potential immunomodulatory role during autoimmune mediated demyelination. Multiple Sclerosis (Houndmills, Basingstoke, England). 14: 577-94. PMID 18566024 DOI: 10.1177/1352458507087468  0.48
2008 Hebb AL, Moore CS, Bhan V, Robertson GS. Targeting apoptosis to treat multiple sclerosis. Current Drug Discovery Technologies. 5: 75-7. PMID 18537570 DOI: 10.2174/157016308783769432  0.48
2008 Moore CS, Hebb AL, Robertson GS. Inhibitor of apoptosis protein (IAP) profiling in experimental autoimmune encephalomyelitis (EAE) implicates increased XIAP in T lymphocytes. Journal of Neuroimmunology. 193: 94-105. PMID 18055022 DOI: 10.1016/J.Jneuroim.2007.10.022  0.48
2008 Hebb AL, Robertson HA, Denovan-Wright EM. Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 18: 339-63. PMID 17913473 DOI: 10.1016/J.Euroneuro.2007.08.002  0.48
2007 Zehntner SP, Bourbonnière L, Moore CS, Morris SJ, Methot D, St Jean M, Lacasse E, Hebb AL, Robertson GS, Durkin J, Gillard JW, Owens T. X-linked inhibitor of apoptosis regulates T cell effector function. Journal of Immunology (Baltimore, Md. : 1950). 179: 7553-60. PMID 18025200 DOI: 10.4049/Jimmunol.179.11.7553  0.48
2007 Hebb AL, Robertson HA. Role of phosphodiesterases in neurological and psychiatric disease. Current Opinion in Pharmacology. 7: 86-92. PMID 17113826 DOI: 10.1016/J.Coph.2006.08.014  0.48
2006 Moore CS, Earl N, Frenette R, Styhler A, Mancini JA, Nicholson DW, Hebb AL, Owens T, Robertson GS. Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis. The Journal of Pharmacology and Experimental Therapeutics. 319: 63-72. PMID 16809479 DOI: 10.1124/Jpet.106.106096  0.48
2005 Hebb AL, Drolet G, Mendella PD, Roach SP, Gauthier MS, Zacharko RM. Intracerebroventricular D-Pen2, D-Pen5-enkephalin administration soon after stressor imposition influences behavioral responsivity to a subsequent stressor encounter in CD-1 mice. Pharmacology, Biochemistry, and Behavior. 82: 453-69. PMID 16290012 DOI: 10.1016/J.Pbb.2005.10.001  0.48
2005 Hebb AL, Poulin JF, Roach SP, Zacharko RM, Drolet G. Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 29: 1225-38. PMID 16242828 DOI: 10.1016/J.Pnpbp.2005.08.008  0.48
2004 Hebb AL, Zacharko RM, Gauthier M, Trudel F, Laforest S, Drolet G. Brief exposure to predator odor and resultant anxiety enhances mesocorticolimbic activity and enkephalin expression in CD-1 mice. The European Journal of Neuroscience. 20: 2415-29. PMID 15525282 DOI: 10.1111/J.1460-9568.2004.03704.X  0.48
2004 Hebb AL, Robertson HA, Denovan-Wright EM. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience. 123: 967-81. PMID 14751289 DOI: 10.1016/J.Neuroscience.2003.11.009  0.48
2003 Hebb AL, Zacharko RM, Bowie JP, Drolet G. Differential startle reactivity following central CCK-8S and systemic Boc CCK-4 administration in mice: antecedent stressor history and testing condition. Behavioral Neuroscience. 117: 704-15. PMID 12931956 DOI: 10.1037/0735-7044.117.4.704  0.48
2003 Hebb AL, Zacharko RM, Gauthier M, Drolet G. Exposure of mice to a predator odor increases acoustic startle but does not disrupt the rewarding properties of VTA intracranial self-stimulation. Brain Research. 982: 195-210. PMID 12915255 DOI: 10.1016/S0006-8993(03)03008-7  0.48
2003 Hebb AL, Zacharko RM. Central D-Ala2-Met5-enkephalinamide mu/delta-opioid receptor activation blocks behavioral sensitization to cholecystokinin in CD-1 mice. Brain Research. 970: 20-34. PMID 12706245  0.48
2003 Hebb AL, Zacharko RM. Central D-Ala2-Met5-enkephalinamide mu/delta-opioid receptor activation reverses the anxiogenic-like properties of cholecystokinin on locomotor and rearing activity in CD-1 mice. Brain Research. 970: 9-19. PMID 12706244  0.48
2003 Hebb AL, Zacharko RM, Dominguez H, Laforest S, Gauthier M, Levac C, Drolet G. Changes in brain cholecystokinin and anxiety-like behavior following exposure of mice to predator odor. Neuroscience. 116: 539-51. PMID 12559109 DOI: 10.1016/S0306-4522(02)00710-8  0.48
2002 Hebb AL, Zacharko RM, Dominguez H, Trudel F, Laforest S, Drolet G. Odor-induced variation in anxiety-like behavior in mice is associated with discrete and differential effects on mesocorticolimbic cholecystokinin mRNA expression. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 27: 744-55. PMID 12431849 DOI: 10.1016/S0893-133X(02)00354-8  0.48
1999 Zacharko RM, MacNeil G, Mendella PD, Hebb AL. Proactive influence of a surgical stressor on locomotor activity, exploration and anxiety-related behaviour following acute footshock in the mouse. Brain Research Bulletin. 48: 283-90. PMID 10229335 DOI: 10.1016/S0361-9230(98)00175-0  0.48
1998 Zacharko RM, Maddeaux C, Hebb AL, Mendella PD, Marsh NJ. Vulnerability to stressor-induced disturbances in self-stimulation from the dorsal and ventral A10 area: differential effects of intraventricular D-Ala2-Met5-enkephalinamide, D-Ala2, N-Me-Phe4, Gly-Ol5-enkephalin, and D-Pen2, D-Pen5-enkephalin administration. Brain Research Bulletin. 47: 237-48. PMID 9865856 DOI: 10.1016/S0361-9230(98)00082-3  0.48
1998 Hebb AL, Zacharko RM, Anisman H. Self-stimulation from the mesencephalon following intraventricular interleukin-2 administration. Brain Research Bulletin. 45: 549-56. PMID 9566497 DOI: 10.1016/S0361-9230(97)00447-4  0.48
Show low-probability matches.